{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T04:19:38Z","timestamp":1769746778653,"version":"3.49.0"},"reference-count":22,"publisher":"Japan Endocrine Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1507\/endocrj.ej20-0577","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T22:12:03Z","timestamp":1605651123000},"page":"361-369","source":"Crossref","is-referenced-by-count":3,"title":["Glucose-lowering effects of 7-day treatment with SGLT2 inhibitor confirmed by intermittently scanned continuous glucose monitoring in outpatients with type 1 diabetes. A pilot study"],"prefix":"10.1507","volume":"68","author":[{"given":"Akira","family":"Kurozumi","sequence":"first","affiliation":[{"name":"First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu 807-8555, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Okada","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu 807-8555, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu 807-8555, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Dandona P, Mathieu C, Phillip M, Hansen L, Griffen SC, et al. (2017) Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 5: 864\u2013876.","DOI":"10.1016\/S2213-8587(17)30308-X"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Rosenstock J, Marquard J, Laffel LM, Neubacher D, Kaspers S, et al. (2018) Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials. Diabetes Care 41: 2560\u20132569.","DOI":"10.2337\/dc18-1749"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Garg SK, Henry RR, Banks P, Buse JB, Davies MJ, et al. (2017) Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med 377: 2337\u20132348.","DOI":"10.1056\/NEJMoa1708337"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Yamada T, Shojima N, Noma H, Yamauchi T, Kadowaki T (2018) Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab 20: 1755\u20131761.","DOI":"10.1111\/dom.13260"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5 Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, et al. (2019) Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 42: 1593\u20131603.","DOI":"10.2337\/dci19-0028"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Lu J, Ma X, Zhou J, Zhang L, Mo Y, et al. (2018) Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes. Diabetes Care 41: 2370\u20132376.","DOI":"10.2337\/dc18-1131"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Viegersky RA, McMahon C (2019) The relationship of hemoglobin A1C to time-in-range as an outcome measure for diabetes. Diabetes Technol Ther 21: 81\u201385.","DOI":"10.1089\/dia.2018.0310"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Kaku K, Isaka H, Sakatani T, Toyoshima J (2019) Efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: a randomized, double-blind, phase 3 trial. Diabetes Obes Metab 21: 2284\u20132293.","DOI":"10.1111\/dom.13807"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Mathieu C, Dandona P, Gillard P, Senior P, Hasslacher C, et al. (2018) Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial. Diabetes Care 41: 1938\u20131946.","DOI":"10.2337\/dc18-0623"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Rodbard HW, Peters AL, Slee A, Cao A, Traina SB, et al. (2017) The effect of canagliflozin, a sodium glucose cotransporter 2 inhibitor, on glycemic end points assessed by continuous glucose monitoring and patient-reported outcomes among people with type 1 diabetes. Diabetes Care 40: 171\u2013180.","DOI":"10.2337\/dc16-1353"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Mathieu C, Dandona P, Phillip M, Oron T, Lind M, et al. (2019) Glucose variables in type 1 diabetes studies with dapagliflozin: pooled analysis of continuous glucose monitoring data from DEPICT-1 and -2. Diabetes Care 42: 1081\u20131087.","DOI":"10.2337\/dc18-1983"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Danne T, Cariou B, Buse JB, Garg SK, Rosenstock J, et al. (2019) Improved time in range and glycemic variability with sotagliflozin in combination with insulin in adults with type 1 diabetes: a pooled analysis of 24-week continuous glucose monitoring data from the in tandem program. Diabetes Care 42: 919\u2013930.","DOI":"10.2337\/dc18-2149"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, et al. (2014) Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 124: 509\u2013514.","DOI":"10.1172\/JCI70704"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, et al. (2014) Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124: 499\u2013508.","DOI":"10.1172\/JCI72227"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Torimoto K, Okada Y, Koikawa K, Tanaka Y (2017) Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring. Diabetol Metab Syndr 9: 60.","DOI":"10.1186\/s13098-017-0258-5"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Araki E, Watada H, Uchigata Y, Tomonaga O, Fujii H, et al. (2020) Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT-5): 52-week results from a randomized, open-label, phase III clinical trial. Diabetes Obes Metab 22: 540\u2013548.","DOI":"10.1111\/dom.13922"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 McCrimmon RJ, Henry RR (2018) SGLT inhibitor adjunct therapy in type 1 diabetes. Diabetologia 61: 2126\u20132133.","DOI":"10.1007\/s00125-018-4671-6"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, et al. (2015) Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 21: 512\u2013517.","DOI":"10.1038\/nm.3828"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Liljenquist JE, Bomboy JD, Lewis SB, Sinclair-Smith BC, Felts PW, et al. (1974) Effects of glucagon on lipolysis and ketogenesis in normal and diabetic men. J Clin Invest 53: 190\u2013197.","DOI":"10.1172\/JCI107537"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Taylor SI, Blau JE, Rother KI (2015) SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 100: 2849\u20132852.","DOI":"10.1210\/jc.2015-1884"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Goldenberg RM, Gilbert JD, Hramiak IM, Woo VC, Zinman B (2019) Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: the STOP DKA protocol. Diabetes Obes Metab 21: 2192\u20132202.","DOI":"10.1111\/dom.13811"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 El Masri D, Ghosh S, Jaber LA (2018) Safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract 137: 83\u201392.","DOI":"10.1016\/j.diabres.2018.01.004"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/68\/3\/68_EJ20-0577\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T03:26:14Z","timestamp":1617420374000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/68\/3\/68_EJ20-0577\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej20-0577","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]}}}